Filter Results:
(128)
Show Results For
- All HBS Web
(545)
- People (2)
- News (136)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
Show Results For
- All HBS Web
(545)
- People (2)
- News (136)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
Page 1 of 128
Results →
Sort by
- September 2003 (Revised March 2007)
- Case
Direvo Biotech AG
Describes the financing and growth decisions facing Direvo, a young German biotech firm with a customer/partner that wants to become an investor. Also discusses the business model for Direvo's directed evolution technology, with applications in both industrial enzymes... View Details
Keywords: Business Model; Decisions; Business Exit or Shutdown; Value; Business Startups; Biotechnology Industry; Germany
Roberts, Michael J., Vincent Dessain, and Anders Sjoman. "Direvo Biotech AG." Harvard Business School Case 804-017, September 2003. (Revised March 2007.)
- 07 Aug 2000
- Research & Ideas
The Business of Biotech
With the sequencing of the human genome running ahead of schedule, the American Stock Exchange's "BTK" biotech index registered an annual increase of 232 percent in February, prompting exuberant headlines ("Move Over,... View Details
- June 3, 2010
- Article
Can Biotech Survive Icahn
By: Bill George
Keywords: Biotechnology Industry
George, Bill. "Can Biotech Survive Icahn." New York Times (June 3, 2010).
- December 2006 (Revised October 2007)
- Case
Monsanto: Realizing Biotech Value in Brazil
By: David E. Bell and Mary L. Shelman
In 2003, Monsanto's patented "Roundup Ready" technology was used illegally on 70-80% of the soybean area in southern Brazil. Under pressure from U.S. soybean growers, who were paying to license the technology, the firm implemented an innovative delivery-based... View Details
Keywords: Plant-Based Agribusiness; Patents; Lawfulness; Emerging Markets; Product Development; Agriculture and Agribusiness Industry; Biotechnology Industry; Brazil
Bell, David E., and Mary L. Shelman. "Monsanto: Realizing Biotech Value in Brazil." Harvard Business School Case 507-018, December 2006. (Revised October 2007.)
- 23 Jul 2001
- Research & Ideas
How Relationships are Building Biotech
Creativity (Oxford University Press) spells it all out. The Missing Link Higgins became interested in this missing link after watching a young biotech company go through two public offerings in the early 1990s. The observations she made... View Details
Keywords: by Martha Lagace & Mallory Stark
- January 2007
- Background Note
Note on Biotech Business Development
By: Richard G. Hamermesh and Robert F. Higgins
Describes the business development process in biotechnology companies. Topics covered include: participants in the licensing process and their interests, the major steps in the licensing process, the terms that are part of most agreements, and the most contentious... View Details
Keywords: Agreements and Arrangements; Entrepreneurship; Intellectual Property; Biotechnology Industry
Hamermesh, Richard G., and Robert F. Higgins. "Note on Biotech Business Development." Harvard Business School Background Note 807-032, January 2007.
- 08 Dec 2003
- Research & Ideas
Why Europe Lags in Pharmaceuticals and Biotech
Governmental, academic, and cultural differences are hurting Europe's chances of creating more competitive pharmaceutical and biotech industries—and not much hope is on the horizon, according to a panel of experts at the 2003 HBS European... View Details
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details
Keywords: Health Care and Treatment; Strategic Planning; Competition; Patents; Innovation and Invention; Pharmaceutical Industry; Biotechnology Industry; United States
Oberholzer-Gee, Felix, and Dennis A. Yao. "Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug." Harvard Business School Case 706-454, December 2005. (Revised August 2006.)
- 13 Jan 2003
- Research & Ideas
Making Biotech Work as a Business
create safer and more effective treatments and, of course, reap profits—industry executives, like hopeful patients, still restlessly wait for relief. Given its scientific potential, said Pisano, biotech continues to bump against several... View Details
- August 2007
- Article
Financial Contracting in Biotech Strategic Alliances
Robinson, David, and Toby E. Stuart. "Financial Contracting in Biotech Strategic Alliances." Journal of Law & Economics 50, no. 3 (August 2007): 559–596.
- March 2007
- Teaching Note
Monsanto: Realizing Biotech Value in Brazil (TN)
By: David E. Bell and Mary L. Shelman
- October 2019
- Case
Kymera Therapeutics: Building a Biotech Execution Plan
By: Peter Barrett, Karim R. Lakhani and Kerry Herman
Barrett, Peter, Karim R. Lakhani, and Kerry Herman. "Kymera Therapeutics: Building a Biotech Execution Plan." Harvard Business School Case 620-017, October 2019.
- 2006
- Book
Science Business: The Promise, the Reality, and the Future of Biotech
By: Gary P. Pisano
Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of... View Details
Pisano, Gary P. Science Business: The Promise, the Reality, and the Future of Biotech. Boston: Harvard Business School Press, 2006.
- October 2007 (Revised July 2013)
- Case
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech
By: Robert F. Higgins, Sophie LaMontagne and Brent Kazan
In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to... View Details
Keywords: Philanthropy; Philanthropy Funding; Innovation; Funding Model; Venture Capital; Partners and Partnerships; Financing and Loans; Investment Funds; Acquisition; Philanthropy and Charitable Giving; Biotechnology Industry; Pharmaceutical Industry; San Diego
Higgins, Robert F., Sophie LaMontagne, and Brent Kazan. "Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech." Harvard Business School Case 808-005, October 2007. (Revised July 2013.)
- October 2012
- Teaching Plan
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech (TP)
By: Robert F. Higgins
This is the teaching note related to HBS case 808005. In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates... View Details
Keywords: Venture Philanthropy; Biotechnology; Funding Philanthropy Venture; Cystic Fibrosis; Foundations; Pharmaceuticals; Mergers and Acquisitions; For-Profit Firms; Venture Capital; Philanthropy and Charitable Giving; Science-Based Business; Nonprofit Organizations; Pharmaceutical Industry; Biotechnology Industry; United States; San Diego
- March 2007
- Teaching Note
Amgen Inc.'s Epogen-Commercializing the First Biotech Blockbuster Drug (TN)
Teaching note to 706454. View Details
- December 2012
- Teaching Note
Gene Patents (A) (TN)
By: Richard G. Hamermesh and Matthew Preble
This is the teaching note for case Gene Patents (A). In March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our... View Details
- November 2016
- Supplement
Alnylam Pharmaceuticals: Building Value from the IP Estate (B)
By: Vicki Sato, Willy Shih and Matt Higgins
The leader of a pioneering biotech company in the siRNA space weighs his options for scaling production capacity in advance of an anticipated commercial launch. Operational complexity and relative merits of in-house manufacturing versus a contractor model are... View Details
Keywords: Pharmaceutical Companies; Pharmaceutical Industry; Biotech; Biotechnology; Operational Complexity; Strategy; Manufacturing; Production; Strategic Planning; Intellectual Property; Biotechnology Industry; United States
Sato, Vicki, Willy Shih, and Matt Higgins. "Alnylam Pharmaceuticals: Building Value from the IP Estate (B)." Harvard Business School Supplement 617-022, November 2016.
- October 2012
- Supplement
Aqua Bounty Courseware
By: Lucy White and Steve Burn-Murdoch
Valuation of a pre-revenue biotech company at IPO using probability trees and real option techniques. Company is based in Massachusetts and lists in London on AIM. Products are genetically-modified fast-growing salmon for fish farmers and disease-prevention drugs and... View Details
- November 2016
- Case
QuintilesIMS: Biosimilar Marketing in England
By: John A. Quelch and Emily C. Boudreau
QuintilesIMS was a leading healthcare consulting firm best known for its data and information offerings as well as its market research and management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical... View Details
Keywords: Health; Pharmaceutical Industry; Biotech; Marketing; Health Care and Treatment; Biotechnology Industry; England
Quelch, John A., and Emily C. Boudreau. "QuintilesIMS: Biosimilar Marketing in England." Harvard Business School Case 517-054, November 2016.